Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Restructuring Costs (2016)

Historic Restructuring Costs for Ligand Pharmaceuticals (LGNYZ) over the last 5 years, with Q4 2016 value amounting to $169000.0.

  • Ligand Pharmaceuticals' Restructuring Costs fell 2777.78% to $169000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $1.0 million, marking a year-over-year increase of 117.65%. This contributed to the annual value of $1.0 million for FY2016, which is 117.65% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Restructuring Costs of $169000.0 as of Q4 2016, which was down 2777.78% from $245000.0 recorded in Q3 2016.
  • In the past 5 years, Ligand Pharmaceuticals' Restructuring Costs ranged from a high of $562000.0 in Q4 2014 and a low of $44000.0 during Q2 2013
  • Moreover, its 5-year median value for Restructuring Costs was $223000.0 (2015), whereas its average is $243736.8.
  • Its Restructuring Costs has fluctuated over the past 5 years, first crashed by 8937.2% in 2013, then surged by 20909.09% in 2014.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Restructuring Costs stood at $356000.0 in 2012, then plummeted by 43.54% to $201000.0 in 2013, then skyrocketed by 179.6% to $562000.0 in 2014, then plummeted by 58.36% to $234000.0 in 2015, then dropped by 27.78% to $169000.0 in 2016.
  • Its last three reported values are $169000.0 in Q4 2016, $245000.0 for Q3 2016, and $374000.0 during Q2 2016.